Evotec Announces First Half Year 2017 Results and Corporate Update

Evotec Announces First Half Year 2017 Results and Corporate Update


Adjusted EBITDA for EVT Execute up 26% to EUR 28.4 m ; Adjusted EBITDA for EVT Innovate of EUR m m) - Multiple new and extended integrated drug discovery agreements, e.g. with Dermira, Asahi Kasei Pharma, Blackthorn Therapeutics and STORM Therapeutics In the first half of 2017, Evotec's Group revenues grew to EUR 103.4 m, an increase of 37% compared to the same period of the previous year . This increase resulted primarily from three factors: the strong performance in the base business, the Cyprotex DMPK business contribution and increased milestone payments.



from Biotech News